SCHEMBL1777784

SCHEMBL1777784

CCOC(=O)n1nc(NC(=O)c2ccccc2N)c2cc(C(=O)OC(C)(C)C)sc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 5/20 0.39
HSD17B10 Q99714 4/20 0.39
HPGD P15428 3/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 2/20 0.36
GAA P10253 1/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
FADS1 O60427 1/20 0.34
CDC25B P30305 2/20 0.34
HTT P42858 1/20 0.34
LMNA P02545 1/20 0.34
CNR2 P34972 1/20 0.34
DDX3X O00571 1/20 0.34
CFTR P13569 1/20 0.34
PDE7A Q13946 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15372469 0.89 ALDH1A1 (0.39) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL15372482 0.87 KDM4E (0.37) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL1780180 0.86 KDM4E (0.38) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL1779377 0.86 ALDH1A1 (0.47) KDM4EALDH1A1HPGDMAPTMEN1
SCHEMBL1780516 0.84 KDM4E (0.38) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL1777894 0.84 ALK (0.43) KDM4EMEN1KMT2AGAAPDE7A
SCHEMBL742599 0.84 KDM4E (0.46) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL1778268 0.83 ALDH1A1 (0.39) KDM4EALDH1A1HSD17B10MAPTMEN1
SCHEMBL1780244 0.83 HSD17B10 (0.38) KDM4EALDH1A1HSD17B10MAPTMEN1
SCHEMBL1781046 0.83 ALDH1A1 (0.38) KDM4EALDH1A1HSD17B10HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 KDM4E 2856/4885ALDH1A1 3557/4885HSD17B10 2498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.